ENXTPA:ALONC

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Oncodesign Société Anonyme, a biotechnology company, conducts research and development work on new therapeutic and diagnostic tools along with pharmaceutical firms, biotech companies, public research institutions, and investment groups. More Details


Snowflake Analysis

Imperfect balance sheet with concerning outlook.

Share Price & News

How has Oncodesign Société Anonyme's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ALONC has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-2.9%

ALONC

2.3%

FR Biotechs

-0.8%

FR Market


1 Year Return

53.8%

ALONC

30.7%

FR Biotechs

-6.6%

FR Market

Return vs Industry: ALONC exceeded the French Biotechs industry which returned 29.8% over the past year.

Return vs Market: ALONC exceeded the French Market which returned -6.2% over the past year.


Shareholder returns

ALONCIndustryMarket
7 Day-2.9%2.3%-0.8%
30 Day-9.4%12.4%0.3%
90 Day-11.7%7.6%-1.4%
1 Year53.8%53.8%30.7%30.7%-4.5%-6.6%
3 Year-13.1%-13.1%-44.4%-44.4%6.8%-2.5%
5 Year-33.1%-33.1%-66.0%-66.2%32.1%12.5%

Price Volatility Vs. Market

How volatile is Oncodesign Société Anonyme's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Oncodesign Société Anonyme undervalued compared to its fair value and its price relative to the market?

42.29x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: ALONC (€10.15) is trading above our estimate of fair value (€8.47)

Significantly Below Fair Value: ALONC is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: ALONC is poor value based on its PE Ratio (42.3x) compared to the XE Biotechs industry average (35.5x).

PE vs Market: ALONC is poor value based on its PE Ratio (42.3x) compared to the French market (18.3x).


Price to Earnings Growth Ratio

PEG Ratio: ALONC's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: ALONC is overvalued based on its PB Ratio (7.9x) compared to the FR Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Oncodesign Société Anonyme forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-0.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALONC's earnings are forecast to decline over the next 3 years (-0.9% per year).

Earnings vs Market: ALONC's earnings are forecast to decline over the next 3 years (-0.9% per year).

High Growth Earnings: ALONC's earnings are forecast to decline over the next 3 years.

Revenue vs Market: ALONC's revenue (16.6% per year) is forecast to grow faster than the French market (6.7% per year).

High Growth Revenue: ALONC's revenue (16.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ALONC's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Oncodesign Société Anonyme performed over the past 5 years?

-1.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALONC has a large one-off gain of €251.7K impacting its June 30 2020 financial results.

Growing Profit Margin: ALONC's current net profit margins (2.8%) are lower than last year (3%).


Past Earnings Growth Analysis

Earnings Trend: ALONC has become profitable over the past 5 years, growing earnings by -1.1% per year.

Accelerating Growth: ALONC's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: ALONC had negative earnings growth (-7.2%) over the past year, making it difficult to compare to the Biotechs industry average (3.1%).


Return on Equity

High ROE: ALONC's Return on Equity (10.7%) is considered low.


Next Steps

Financial Health

How is Oncodesign Société Anonyme's financial position?


Financial Position Analysis

Short Term Liabilities: ALONC's short term assets (€23.7M) exceed its short term liabilities (€16.3M).

Long Term Liabilities: ALONC's short term assets (€23.7M) exceed its long term liabilities (€14.6M).


Debt to Equity History and Analysis

Debt Level: ALONC's debt to equity ratio (52%) is considered high.

Reducing Debt: ALONC's debt to equity ratio has increased from 1.2% to 52% over the past 5 years.

Debt Coverage: ALONC's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if ALONC's interest payments on its debt are well covered by EBIT.


Balance Sheet


Next Steps

Dividend

What is Oncodesign Société Anonyme current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALONC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALONC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALONC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALONC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALONC's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.5yrs

Average management tenure


CEO

Philippe Genne

10.42yrs

Tenure

€204,420

Compensation

Dr. Philippe Genne, Ph.D., Founded Oncodesign Société Anonyme, serves as its Chairman of the Board and has been its Chief Executive Officer since May 18, 2010.


Leadership Team

NamePositionTenureCompensationOwnership
Philippe Genne
Founder10.42yrs€204.42kno data
Arnaud Lafforgue
Chief Financial & Administrative Officer2.5yrsno datano data
Jan Hoflack
Chief Scientific & Operating Officerno datano datano data
Catherine Genne
Deputy Managing Directorno data€24.34kno data
Olivier Duchamp
Member of Executive Board12.75yrsno datano data
Francis Bichat
Member of Executive Board12.75yrsno datano data
Stephane Gerart
Chief Information Officer & Head of Artificial Intelligence Business Unit0.083yrno datano data
Xavier Morge
Chief Corporate Business Development Officer0.083yrno datano data
Thierry Billoué
Head of Human Resourcesno datano datano data
Fabrice Viviani
GM, Senior EVP & Head of Oncodesign Service Business Unitno datano datano data

6.5yrs

Average Tenure

55yo

Average Age

Experienced Management: ALONC's management team is seasoned and experienced (6.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Oncodesign Société Anonyme's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Oncodesign Société Anonyme
  • Ticker: ALONC
  • Exchange: ENXTPA
  • Founded: 1995
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €69.406m
  • Shares outstanding: 6.84m
  • Website: https://www.oncodesign.com

Number of Employees


Location

  • Oncodesign Société Anonyme
  • 20 rue Jean Mazen
  • B.P. 27627
  • Dijon
  • Burgundy
  • 21076
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALONCENXTPA (Euronext Paris)YesOrdinary SharesFREURApr 2014

Biography

Oncodesign Société Anonyme, a biotechnology company, conducts research and development work on new therapeutic and diagnostic tools along with pharmaceutical firms, biotech companies, public research insti ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/19 20:54
End of Day Share Price2020/10/19 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.